Recombinant Anti-doxorubicin x Anti-EGFR Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-doxorubicin specificity or anti-EGFR specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can be used in pretargeting system and deliver toxin to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
There are currently no customer reviews or questions for Recombinant Anti-doxorubicin x Anti-EGFR Bispecific Antibody (scFv-Fc) (BSCFV-151). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS